Refine
Has Fulltext
- yes (23)
Is part of the Bibliography
- yes (23)
Year of publication
Document Type
- Journal article (13)
- Doctoral Thesis (10)
Keywords
- recurrence (23) (remove)
Institute
- Pathologisches Institut (5)
- Neurochirurgische Klinik und Poliklinik (4)
- Urologische Klinik und Poliklinik (4)
- Klinik und Poliklinik für Allgemein-, Viszeral-, Gefäß- und Kinderchirurgie (Chirurgische Klinik I) (3)
- Medizinische Klinik und Poliklinik I (3)
- Institut für diagnostische und interventionelle Radiologie (Institut für Röntgendiagnostik) (2)
- Comprehensive Cancer Center Mainfranken (1)
- Graduate School of Life Sciences (1)
- Institut für Anatomie und Zellbiologie (1)
- Institut für Humangenetik (1)
Systemic chemotherapy of pediatric recurrent ependymomas: results from the German HIT-REZ studies
(2021)
Purpose
Survival in recurrent ependymoma (EPN) depends mainly on the extent of resection achieved. When complete resection is not feasible, chemotherapy is often used to extend progression-free and overall survival. However, no consistent effect of chemotherapy on survival has been found in patients with recurrent EPN.
Methods
Systemic chemotherapeutic treatment of 138 patients enrolled in the German HIT-REZ-studies was analyzed. Survival depending on the use of chemotherapy, disease-stabilization rates (RR), duration of response (DOR) and time to progression (TTP) were estimated.
Results
Median age at first recurrence was 7.6 years (IQR: 4.0–13.6). At first recurrence, median PFS and OS were 15.3 (CI 13.3–20.0) and 36.9 months (CI 29.7–53.4), respectively. The Hazard Ratio for the use of chemotherapy in local recurrences in a time-dependent Cox-regression analysis was 0.99 (CI 0.74–1.33). Evaluable responses for 140 applied chemotherapies were analyzed, of which sirolimus showed the best RR (50%) and longest median TTP [11.51 (CI 3.98; 14.0) months] in nine patients, with the strongest impact found when sirolimus was used as a monotherapy. Seven patients with progression-free survival > 12 months after subtotal/no-resection facilitated by chemotherapy were found. No definitive survival advantage for any drug in a specific molecularly defined EPN type was found.
Conclusion
No survival advantage for the general use of chemotherapy in recurrent EPN was found. In cases with incomplete resection, chemotherapy was able to extend survival in individual cases. Sirolimus showed the best RR, DOR and TTP out of all drugs analyzed and may warrant further investigation.
Purpose
To investigate the association of patients’ sex with recurrence and disease progression in patients treated with intravesical bacillus Calmette–Guérin (BCG) for T1G3/HG urinary bladder cancer (UBC).
Materials and methods
We analyzed the data of 2635 patients treated with adjuvant intravesical BCG for T1 UBC between 1984 and 2019. We accounted for missing data using multiple imputations and adjusted for covariate imbalance between males and females using inverse probability weighting (IPW). Crude and IPW-adjusted Cox regression analyses were used to estimate the hazard ratios (HR) with their 95% confidence intervals (CI) for the association of patients’ sex with HG-recurrence and disease progression.
Results
A total of 2170 (82%) males and 465 (18%) females were available for analysis. Overall, 1090 (50%) males and 244 (52%) females experienced recurrence, and 391 (18%) males and 104 (22%) females experienced disease progression. On IPW-adjusted Cox regression analyses, female sex was associated with disease progression (HR 1.25, 95%CI 1.01–1.56, p = 0.04) but not with recurrence (HR 1.06, 95%CI 0.92–1.22, p = 0.41). A total of 1056 patients were treated with adequate BCG. In these patients, on IPW-adjusted Cox regression analyses, patients’ sex was not associated with recurrence (HR 0.99, 95%CI 0.80–1.24, p = 0.96), HG-recurrence (HR 1.00, 95%CI 0.78–1.29, p = 0.99) or disease progression (HR 1.12, 95%CI 0.78–1.60, p = 0.55).
Conclusion
Our analysis generates the hypothesis of a differential response to BCG between males and females if not adequately treated. Further studies should focus on sex-based differences in innate and adaptive immune system and their association with BCG response.
Protocadherins (PCDHs) belong to the cadherin superfamily and represent the largest subgroup of calcium-dependent adhesion molecules. In the genome, most PCDHs are arranged in three clusters, α, β, and γ on chromosome 5q31. PCDHs are highly expressed in the central nervous system (CNS). Several PCDHs have tumor suppressor functions, but their individual role in primary brain tumors has not yet been elucidated. Here, we examined the mRNA expression of PCDHGC3, a member of the PCDHγ cluster, in non-cancerous brain tissue and in gliomas of different World Health Organization (WHO) grades and correlated it with the clinical data of the patients. We generated a PCDHGC3 knockout U343 cell line and examined its growth rate and migration in a wound healing assay. We showed that PCDHGC3 mRNA and protein were significantly overexpressed in glioma tissue compared to a non-cancerous brain specimen. This could be confirmed in glioma cell lines. High PCDHGC3 mRNA expression correlated with longer progression-free survival (PFS) in glioma patients. PCDHGC3 knockout in U343 resulted in a slower growth rate but a significantly faster migration rate in the wound healing assay and decreased the expression of several genes involved in WNT signaling. PCDHGC3 expression should therefore be further investigated as a PFS-marker in gliomas. However, more studies are needed to elucidate the molecular mechanisms underlying the PCDHGC3 effects.
Eine prämature Kraniosynostose bezeichnet eine vorzeitige Verknöcherung einer oder mehrerer Schädelnähte. Ihre Entstehung ist von multiplen Faktoren abhängig. So scheinen genetische Faktoren, das Rauchen der Mutter oder die Einnahme bestimmter Medikamente in der Schwangerschaft, Schilddrüsen- und Stoffwechselerkrankungen einen Einfluss zu haben. Die Koronarnahtsynostose stellt mit einer Inzidenz von 20 % die zweithäufigste Form der prämaturen Synostosen dar. Bei dem vorzeitigen unilateralen Nahtverschluss kommt es zur Entwicklung eines anterioren Plagiozephalus. Bei einer beidseitigen Koronarnahtsynostose entsteht ein brachy-turrizephaler Schädel. Die frühzeitige Diagnose ist wichtig, damit die betroffenen Kinder frühestmöglich in ein optimales Betreuungs- und Therapiekonzept eingebunden werden können. Bei Einzelnahtsynostosen sind meist bereits die untersuchten klinischen Parameter zur Diagnosestellung ausreichend und sollten um eine Sonographie und Röntgenaufnahmen in zwei Ebenen erweitert werden. Eine Indikation zur operativen Intervention stellt der Nachweis einer pathologischen intrakraniellen Drucksteigerung dar. Das Frontoorbitale Advancement ist die Operationstechnik der Wahl bei der Koronarnahtsynostose.
Ziel der vorliegenden Dissertationsarbeit war die Weiterentwicklung bestehender kephalometrischer und kraniometrischer Messverfahren nach Slomic et al.. Dabei sollten der operative Therapieerfolg und der weitere Verlauf hinsichtlich einer Rezidivgefahr bewertet werden. In der vorliegenden Arbeit wurden Röntgenbilder des Carniofacialen Centrums Würzburg kraniometrisch ausgewertet. Das Patient*innenkollektiv wurde in zwei Gruppen untergliedert, und zwar Patient*innen mit einseitiger, nonsyndromaler Koronarnahtsynostose und Patient*innen mit beidseitiger, syndromaler Koronarnahtsynostose. Zur statistischen Auswertung erfolgte in beiden Patient*innengruppen die Untersuchung der Röntgenbilder zu vier festgelegten Zeitpunkten (00, 01, 02, 03). Die statistische Auswertung erfolgte mit dem Programm SPSS. Untersucht wurden der Gruppeneffekt und der Zeiteffekt hinsichtlich der 13 Strecken (LI, BRSt, BRPa, NO, PIS; SN, PIN, HI, NSt, SBR, PIBR, WI, AS) und fünf Winkel (ANS, SNBR, PIBRPa, BRNST, PISN). Da es in der Literatur eine unzureichende Erfassung von Strecken und Winkeln gibt, die die Veränderungen des Schädelwachstums erfassen, wurden die Strecken BRSt, BRPa, NSt, PIBR und AS sowie die fünf oben genannten Winkel neu definiert und entwickelt. Für die Röntgenzeitpunkte 00 und 01 zeigten sich für die Strecken und Winkel LI, BRSt, HI, NSt, SBR, PIBR, WI, PIBRPa und BRNST signifikante Unterschiede. Dies kann als OP-Erfolg gewertet werden. Der Kopf wird intraoperativ flacher und schmäler. Im weiteren Verlauf zeigte sich bei den Strecken BRSt, HI, PIBR und WI sowie bei den Winkeln PIBRPa und BRNST ein signifikanter Unterschied. Der Kopf wächst rezidivierend turrizephal. Im weiteren Untersuchungszeitraum wurde lediglich für die Strecken BRPa und AS ein signifikanter Unterschied ausgemacht. Zum einen Anzeichen eines im Wachstumsverlauf einsetzenden Rezidivs. Der Kopf wird wieder turrizephaler (BRPa). Zum anderen ist es Ausdruck einer beginnenden Mittelgesichtshypoplasie (AS). Weiterhin konnte über die Strecken SBR und PIBR gezeigt werden, dass Patient*innen mit beidseitiger Synostose eine turrizephalere Kopfform als die Vergleichsgruppe mit einseitiger Synostose aufweisen. Auffällig war außerdem das Ergebnis der beiden Winkel ANS und SNBR. Sie belegen, dass Patient*innen mit beidseitiger Synostose und Syndrom eine Mittelgesichtshypoplasie aufweisen. Als Fazit lässt sich sagen, dass die Strecken LI, BRSt, BRPa, HI, SBR, WI und AS sowie die Winkel SNBR, PIBRPa und ANS für weitere Untersuchungen geeignet scheinen.
A relevant issue on the treatment of adrenocortical carcinoma (ACC) concerns the optimal duration of adjuvant mitotane treatment. We tried to address this question, assessing whether a correlation exists between the duration of adjuvant mitotane treatment and recurrence-free survival (RFS) of patients with ACC. We conducted a multicenter retrospective analysis on 154 ACC patients treated for ≥12 months with adjuvant mitotane after radical surgery and who were free of disease at the mitotane stop. During a median follow-up of 38 months, 19 patients (12.3%) experienced recurrence. We calculated the RFS after mitotane (RFSAM), from the landmark time-point of mitotane discontinuation, to overcome immortal time bias. We found a wide variability in the duration of adjuvant mitotane treatment among different centers and also among patients cared for at the same center, reflecting heterogeneous practice. We did not find any survival advantage in patients treated for longer than 24 months. Moreover, the relationship between treatment duration and the frequency of ACC recurrence was not linear after stratifying our patients in tertiles of length of adjuvant treatment. In conclusion, the present findings do not support the concept that extending adjuvant mitotane treatment over two years is beneficial for ACC patients with low to moderate risk of recurrence.
We have previously identified serum miR-483-5p as a preoperative diagnosis and prognosis biomarker for adrenocortical cancer (ACC). Here, we aimed to determine whether circulating miR-483-5p levels measured 3 months post-operatively distinguished patients with good prognosis (no recurrence for at least 3 years; NR3yrs) from patients with poor prognosis (recurrence or death within 3 years after surgery; R < 3yrs). We conducted a single-center retrospective analysis using sera from 48 patients with ACC that were initially non-metastatic and treated by surgery. Sera sampled within 3 months after surgery were available in 26 patients. MiR-483-5p absolute circulating levels were measured using quantitative PCR. Thirteen patients showed a recurrence before 3 years (=R < 3yrs). Thirteen patients showed no recurrence within 3 years, including 11 patients with a follow-up longer than 3 years (=NR3yrs). Serum miR-483-5p levels were higher in R < 3yrs than in NR3yrs: 1,541,990 ± 428,377 copies/mL vs. 388,457 ± 62,169 copies/mL (p = 0.002). Receiver operating characteristic analysis showed that a value of 752,898 copies/mL distinguished R < 3yrs from NR3yrs with 61.5% sensitivity (CI 31.6–86.1) and 100% specificity (CI 71.5–100) with an area under the curve of 0.853. Patients with a value below this threshold had a significantly longer recurrence-free and overall survival. In multivariate analysis, miR-483-5p provided the single best prognostic value for recurrence-free survival (RFS) (hazard ratio (HR) for recurrence 5.98, p < 0.011) but not for overall survival. Our study suggests that serum miR-483-5p is a potent early post-operative biomarker for ACC prognosis that might be a better predictor of RFS than currently used markers.
Inhibition of the protein kinase MPS1, a mitotic spindle-checkpoint regulator, reinforces the effects of multiple therapies against glioblastoma multiforme (GBM) in experimental settings. We analyzed MPS1 mRNA-expression in gliomas WHO grade II, III and in clinical subgroups of GBM. Data were obtained by qPCR analysis of tumor and healthy brain specimens and correlated with the patients’ clinical data. MPS1 was overexpressed in all gliomas on an mRNA level (ANOVA, p < 0.01) and correlated with tumor aggressiveness. We explain previously published conflicting results on survival: high MPS1 was associated with poorer long term survival when all gliomas were analyzed combined in one group (Cox regression: t < 24 months, p = 0.009, Hazard ratio: 8.0, 95% CI: 1.7–38.4), with poorer survival solely in low-grade gliomas (LogRank: p = 0.02, Cox regression: p = 0.06, Hazard-Ratio: 8.0, 95% CI: 0.9–66.7), but not in GBM (LogRank: p > 0.05). This might be due to their lower tumor volume at the therapy start. GBM patients with high MPS1 mRNA-expression developed clinical symptoms at an earlier stage. This, however, did not benefit their overall survival, most likely due to the more aggressive tumor growth. Since MPS1 mRNA-expression in gliomas was enhanced with increasing tumor aggressiveness, patients with the worst outcome might benefit best from a treatment directed against MPS1.
Aberrant methylation of DNA is supposed to be a major and early driver of colonic adenoma development, which may result in colorectal cancer (CRC). Although gene methylation assays are used already for CRC screening, differential epigenetic alterations of recurring and nonrecurring colorectal adenomas have yet not been systematically investigated. Here, we collected a sample set of formalin‐fixed paraffin‐embedded colorectal low‐grade adenomas (n = 72) consisting of primary adenomas without and with recurrence (n = 59), recurrent adenomas (n = 10), and normal mucosa specimens (n = 3). We aimed to unveil differentially methylated CpG positions (DMPs) across the methylome comparing not only primary adenomas without recurrence vs primary adenomas with recurrence but also primary adenomas vs recurrent adenomas using the Illumina Human Methylation 450K BeadChip array. Unsupervised hierarchical clustering exhibited a significant association of methylation patterns with histological adenoma subtypes. No significant DMPs were identified comparing primary adenomas with and without recurrence. Despite that, a total of 5094 DMPs (false discovery rate <0.05; fold change >10%) were identified in the comparisons of recurrent adenomas vs primary adenomas with recurrence (674; 98% hypermethylated), recurrent adenomas vs primary adenomas with and without recurrence (241; 99% hypermethylated) and colorectal adenomas vs normal mucosa (4179; 46% hypermethylated). DMPs in cytosine‐phosphate‐guanine (CpG) islands were frequently hypermethylated, whereas open sea‐ and shelf‐regions exhibited hypomethylation. Gene ontology analysis revealed enrichment of genes associated with the immune system, inflammatory processes, and cancer pathways. In conclusion, our methylation data could assist in establishing a more robust and reproducible histological adenoma classification, which is a prerequisite for improving surveillance guidelines.
Despite its significant overexpression in several malignant neoplasms, the expression of RPS27 in the central nervous system (CNS) is widely unknown. We identified the cell types expressing RPS27 in the CNS under normal and disease conditions. We acquired specimens of healthy brain (NB), adult pilocytic astrocytoma (PA) World Health Organization (WHO) grade I, anaplastic PA WHO grade III, gliomas WHO grade II/III with or without isocitrate dehydrogenase (IDH) mutation, and glioblastoma multiforme (GBM). RPS27 protein expression was examined by immunohistochemistry and double-fluorescence staining and its mRNA expression quantified by RT-PCR. Patients’ clinical and tumor characteristics were collected retrospectively. RPS27 protein was specifically expressed in tumor cells and neurons, but not in healthy astrocytes. In tumor tissue, most macrophages were positive, while this was rarely the case in inflamed tissue. Compared to NB, RPS27 mRNA was in mean 6.2- and 8.8-fold enhanced in gliomas WHO grade II/III with (p < 0.01) and without IDH mutation (p = 0.01), respectively. GBM displayed a 4.6-fold increased mean expression (p = 0.02). Although RPS27 expression levels did not affect the patients’ survival, their association with tumor cells and tumor-associated macrophages provides a rationale for a future investigation of a potential function during gliomagenesis and tumor immune response.
Krebserkrankungen stellen eine lebensverändernde und potentiell letale Diagnose dar. Orale Zytostatika stellen eine vielversprechende Therapiemöglichkeit dar. Ein häufig eingesetztes orales Zytostatikum ist Capecitabin. Durch den Einsatz von oralen Chemotherapeutika ergeben sich viele Vorteile. Grundlegende Voraussetzung für den Einsatz der Tablettenform ist allerdings eine äquivalente Wirksamkeit. Diese hängt entscheidend von ausreichender Adhärenz der Patienten ab.
In dieser Studie konnte bei der Auswertung des MARS-D gezeigt werden, dass 25 % der Studienteilnehmer nicht ausreichend adhärent waren. Häufigster Grund für Nicht-Adhärenz war das Vergessen der Medikamenteneinnahme. Ein weiteres, wichtiges Ergebnis dieser Pilotstudie war, dass die Probanden ihre Adhärenz subjektiv deutlich höher einschätzten (M im VAS 97,72) als sich bei der Auswertung des MARS-D bestätigen ließ.
Die Erkennung und Behandlung psychischer Beeinträchtigungen und Erkrankungen ist bei der Betreuung von Krebspatienten entscheidend. Fear of progression (FOP) ist die am häufigsten geäußerte Angst von Krebspatienten. Diese Studie konnte die Bedeutung von FOP deutlich zeigen: bei 38 % der Probanden konnte eine dysfunktionale Form der FOP nachgewiesen werden. Nur vier Studienteilnehmer nutzten allerdings psychosomatische/psychiatrische Unterstützungmöglichkeiten.
Die Single-Item Analyse des PA-F-KF zeigten sich Ängste im Vordergrund stehend, welche den Bereich Familie betrafen. Überraschenderweise ließ sich zwischen der häufigsten Nebenwirkung Hand-Fuß-Syndrom und FOP kein signifikanter Zusammenhang nachweisen. Dagegen konnten stark signifikante Zusammenhänge zwischen dem Auftreten von Diarrhoen, Übelkeit, Erschöpfung und dysfunktionaler FOP gezeigt werden.